PT  - JOURNAL ARTICLE
AU  - Eckl-Dorna, J.
AU  - Morgenstern, C.
AU  - Poglitsch, K.
AU  - Arnoldner, T.
AU  - Gangl, K.
AU  - Bartosik, T.
AU  - Campion, N.J.
AU  - Tu, A.
AU  - Stanek, V.
AU  - Schneider, S.
AU  - Bangert, C.
TI  - Dupilumab dampens mucosal type 2 response during acetylsalicylic acid challenge in N-ERD patients
AID  - 10.1101/2024.06.07.24308587
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.07.24308587
4099  - http://medrxiv.org/content/early/2024/06/07/2024.06.07.24308587.short
4100  - http://medrxiv.org/content/early/2024/06/07/2024.06.07.24308587.full
AB  - Rationale Non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is characterized by the clinical triad of hypersensitivity to NSAIDs, nasal polyposis, and asthma. The cells and mediators causing acute symptoms when driving the hypersensitivity reaction to acetylsalicylic acid (ASA) ingestion, remain poorly defined.Objectives To investigate the dynamics of nasal mediators during ASA provocation in N-ERD patients before and twenty-four weeks after therapy with the IL-4 receptor alpha-blocking antibody dupilumab.Methods Nasal mucosal lining fluids of patients with N-ERD, chronic rhinosinusitis patients with nasal polyp (CRSwNP) and healthy disease controls were collected at selected time points up to two hours after ASA provocation. Analysis of thirty-three different inflammatory mediators as well as transcriptomic profiling was performed. In N-ERD patients, provocation was repeated after twenty-four weeks of dupilumab therapy.Measurements and Main Results Sixty minutes after provocation with ASA, N-ERD patients showed a significant increase in type 2 associated cytokines (i.e., TSLP, IL-5, and eotaxin-3) as compared to the other patient groups. This effect was diminished after twenty-four weeks of dupilumab therapy and was independent of the development of ASA tolerance. Transcriptomics revealed dampened upregulation of type 2 associated pathways genes (i.e., AREG) as well as enhanced downregulation of lipid (i.e., ALOX15) and peroxisome metabolisms (i.e., NOS2) at ASA provocation after dupilumab therapy.Conclusions Treatment with dupilumab leads to reduced nasal type 2 cytokine secretion and distinct changes in transcriptomic profile during ASA provocation, but changes in type 2 mediators show no association with tolerance development.Competing Interest StatementSS served as a speaker and/or consultant and/or advisory board member for Sanofi, GSK and Novartis. SS is an investigator for Novartis, GSK and AstraZeneca (grants paid to his institution). CB served as a speaker and/or consultant and/or advisory board member for Almirall, Mylan, LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, and AbbVie. CB is an investigator for Novartis, Sanofi, AbbVie, Eli Lilly, LEO Pharma and Galderma (grants paid to her institution). JED served as a speaker and/or consultant and/or advisory board member and investigator (grants paid to her institution) for Sanofi, AstraZeneca and GSK.Clinical TrialNCT04442256 (ClinicalTrials.gov) and 2019-004889-18 (EudraCT)Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Medical University of Vienna (EK 1044/2020) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAD50000000565. Further information about EGA can be found at https://ega-archive.org and "The European Genome-phenome Archive of human data consented for biomedical research".ASAacetylsalicylic acidCRSwNPChronic rhinosinusitis with nasal polypsCOX-1Cyclooxygenase-1CysLTsCysteinyl leukotrienesFEV1Forced expiratory volume in one minuteN-ERDNon-steroidal anti-inflammatory drug(NSAID)exacerbated respiratory diseaseTPSTotal Polyp ScoreILC2Type 2 innate lymphoid cellsnMLFNasal mucosal lining fluidUPSITUniversity of Pennsylvania Smell Identification TestSNOT-22Sino-nasal Outcome Test